Table 1.
Clinical-pathological parameters of the study cohorts
| Quantitative real-time PCR | Immunohistochemistry | |||
|---|---|---|---|---|
|
|
||||
| Cancer n=51 (%) | Normal n=51 (%) | Cancer n=143 (%) | Normal n=21 (%) | |
| Sex | ||||
| male | 34 (66.6) | 35 (68.6) | 93 (65.0) | 16 (76.1) |
| female | 17 (33.3) | 16 (31.4) | 50 (35.0) | 5 (23.9) |
| Age | ||||
| mean | 62.5 | 62.0 | 63.2 | 55.7 |
| min-max | 36-86 | 36-86 | 33-85 | 28-77 |
| Pathological stage | ||||
| pT1 | 28 (54.9) | n.a. | 53 (37.1) | n.a. |
| pT2 | 7 (13.7) | n.a. | 28 (19.6) | n.a. |
| pT3 | 16 (31.4) | n.a. | 47 (32.9) | n.a. |
| pT4 | 0 (0) | n.a. | 2 (1.4) | n.a. |
| lymph node metastasis | 2 (3.9) | n.a. | 8 (5.6) | n.a. |
| distant metastasis | 7 (13.7) | n.a. | 17 (11.9) | n.a. |
| Grading | ||||
| grade 1 | 4 (7.8) | n.a. | 38 (26.6) | n.a. |
| grade 2 | 39 (76.5) | n.a. | 89 (62.2) | n.a. |
| grade 3 | 7 (13.7) | n.a. | 3 (2.1) | n.a. |
| grade 4 | 1 (1.9) | n.a. | 0 (0) | n.a. |
n.a., not applicable.